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a piglet survival model
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Richard A. Jonas, MD
Objective: The efficacy of aprotinin in reducing blood loss after cardiopulmonary bypass is well established,
although its neuroprotective potential is less well known. Furthermore, there is controversy regarding optimal
dosing and possible renal complications.
Methods: Fifty-four piglets were randomized to one of 3 cardiopulmonary bypass groups designed to carry the
risk of postoperative cerebral and renal dysfunction: circulatory arrest at 25C and ultra–low flow bypass (10 mL $
kg1 $ min1) at either 25C or 34C. Animals were randomized to the following groups: control (no aprotinin),
low dose (30,000 KIU/kg into prime only), standard full dose (30,000 KIU/kg bolus administered intravenously
into prime plus 10,000 KIU/kg infusion), and double full dose. The tissue oxygenation index was monitored by
means of near-infrared spectroscopy. Neurologic functional and histologic scores and creatinine and blood urea
nitrogen values were outcomes of interest.
Results: Aprotinin significantly improved neurologic scores on postoperative day 1 after ultra–low-flow bypass
at 25C or 34C (P< .01) but not after hypothermic circulatory arrest (P ¼ .57). Linear regression indicated
a strong dose-response relationship, with higher aprotinin doses having the best neurologic scores. During
low-flow bypass, a higher tissue oxygenation index was correlated with a higher aprotinin dose (P<.05). Apro-
tinin dose had no significant effect on creatinine or blood urea nitrogen values on day 1. Low body weight was the
only predictor of high blood urea nitrogen values (r ¼0.39, P< .01).
Conclusion: Aprotinin significantly improves neurologic recovery without compromising renal function in the
young piglet.C
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SAprotinin is a broad-spectrum serine protease inhibitor iso-
lated from bovine lung. It has anti-inflammatory effects
and reduces postoperative blood loss after cardiopulmonary
bypass (CPB) by blocking complement activation and
reduction of fibrinolysis through inhibition of trypsin, plas-
min, and kallikrein.1,2 However, the optimal dose of aproti-
nin has been controversial. Levy and colleagues2 reported
that both low and high doses reduced postoperative blood
loss. Kawasuji and associates3 reported that low-dose apro-
tinin could reduce postoperative blood loss. In general, the
dose used for adults in contrast to pediatric dosing has not
varied according to body surface area, and the blood level
has not been monitored. Nuttall and coworkers4 reported
that the dose of aprotinin adjusted by body weight was help-
ful to obtain the optimal plasma concentration of aprotinin
and to avoid overdosing.
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possible adverse effects of aprotinin, such as myocardial
infarction or renal dysfunction.5-7 In 2006, Mangano and
coworkers8 reported, in an influential article in the New
England Journal of Medicine, that aprotinin increased the
risk of renal failure requiring dialysis, myocardial infarction,
and stroke. Preliminary results of a prospective study in
adults suggesting a possibly higher mortality because of
bleeding led the US Food and Drug Administration to rec-
ommend that aprotinin not be marketed for any application,
including pediatric CPB.
In pediatric cardiac surgery major neurologic injury, such
as choreoathetosis and loss of developmental potential, re-
main feared complications. The role of genetic factors, prena-
tal cerebral blood flow, and socioeconomic factors, as well as
postoperative intensive care unit management, have been re-
ported as influencing developmental outcome; nevertheless,
2 carefully designed prospective studies have implicated in-
traoperative factors as important determinants of develop-
mental outcome after pediatric cardiac surgery. Aprotinin,
however, has never been implicated as a cause of neurologic
injury in children, despite its widespread use in pediatric car-
diac surgery. In fact, several investigators have demonstrated
the potential of aprotinin for neuroprotection. Kamiya and
colleagues9 reported that aprotinin improved preservation
of cerebral adenosine triphosphate and reduced cerebral wa-
ter content after ischemia. Aoki and associates10 used a piglet
model and magnetic resonance spectroscopy to show thatardiovascular Surgery c Volume 137, Number 6 1521




ANOVA ¼ analysis of variance
BUN ¼ blood urea nitrogen
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
HCA ¼ hypothermic circulatory arrest
HS ¼ histologic score
NDS ¼ neurologic deficit score
NIRS ¼ near-infrared spectroscopy
TOI ¼ tissue oxygenation index
ULF ¼ ultra low flow
aprotinin improved acute recovery of cerebral energy metab-
olism after deep hypothermic circulatory arrest (DHCA),
possibly through preservation of endothelial function in
the cerebral microvasculature. Anttila and coworkers11
used cerebral intravital microscopy to demonstrate that apro-
tinin reduced inflammation and improved neurologic func-
tional outcome after DHCA using a piglet survival model
and the full pediatric Hammersmith dose regimen, although
it did not improve histologic score (HS).
Reports in the neuroscience literature have suggested
that serine protease inhibitors protect neurons from ische-
mic injury.12-14 Nicole and associates15 described reduced
excitotoxic neuronal injury with exposure to the serpin
plasminogen activator inhibitor-1, and Lebeurrier and col-
leagues16 reported that neuroserpin also protects neurons
from glutamatergic excitotoxic neuronal cell death. Using
a similar neuronal cell culture model, we reported that
aprotinin also has a direct and dose-dependent neuro-
protective effect against neuronal cell death caused by
N-methyl-D-aspartate.17
The purpose of this piglet survival study was to investi-
gate the optimal dose of aprotinin for neuroprotection and
the effect of aprotinin on renal function.
MATERIALS AND METHODS
Animals
Fifty-four young (27  5 days) Yorkshire piglets weighting 10.4  1.4
kg were studied. All animals received humane care in accordance with the
‘‘Principles of laboratory animal care’’ formulated by the National Society
for Medical Research and the ‘‘Guide for the care and use of laboratory an-
imals’’ prepared by the Institute of Laboratory Animal Resources, National
Research Council, and published by the National Academy Press, revised in
1996. This study was approved by the Institutional Animal Care and Use
Committee of the Children’s National Medical Center.
Surgical Preparation
After premedication with an intramuscular injection of ketamine (20 mg/
kg) and xylazine (4 mg/kg), the piglets were intubated with 5-mm cuffed en-
dotracheal tubes and ventilated with 21% oxygen at a respiratory rate of be-
tween 12 and 16 breaths/min to achieve an arterial PCO2 of 40 mm Hg with
a pressure cycle ventilator (Sechrist IV-100BVentilator; Sechrist Industries,
Inc, Anaheim, Calif). After induction with an intravenous bolus, injection of
fentanyl (50 mg/kg) and pancuronium (0.5 mg/kg), anesthesia was main-1522 The Journal of Thoracic and Cardiovascular Sutained with continuous infusion of fentanyl (25 mg $ kg1 $ h1), midazolam
(0.2 mg $ kg1 $ h1), and pancuronium (0.2 mg $ kg1 $ h1) throughout the
entire experiment. Temperature probes were placed into the esophagus and
rectum. Optodes for near-infrared spectroscopy (NIRS) were placed over
the frontal lobes, with an interoptode distance of 4.0 cm. The receiving op-
tode incorporates 3 detectors. The piglets were in the supine position, and all
surgical procedures were performed under sterile conditions. For pressure
monitoring, blood sampling, and drug infusion, a catheter (19-gauge Intra-
cath; Becton Dickinson, Sandy, Utah) was inserted into the abdominal aorta
through the left superficial femoral artery, and another catheter was intro-
duced through the right femoral vein into the inferior vena cava. After sys-
temic heparinization (300 IU/kg), the chest was entered through a right
anterolateral thoracotomy in the third intercostal space, an 8F arterial
cannula (Bio-Medicus; Medtronic, Inc, Eden Prairie, Minn) was inserted
into the abdominal aorta through the right femoral artery, and a 28F cannula
(Harvey; Bard, Tewksbury,Mass) was inserted for venous drainage through
the right atrial appendage.
Experimental Protocol
The study protocol is depicted in Figure 1. Details of the survival piglet
model have been described elsewhere.18-20 The 54 piglets were each ran-
domly assigned to one of 12 settings (3 bypass conditions and 4 aprotinin
dosings), with 4 piglets for each setting. Animals were weaned from the ven-
tilator and extubated early the next morning. Neurologic evaluationwas per-
formed every day postoperatively. Animals were killed on postoperative
day 4 for histologic assessment.
Experimental Groups
Brain damage according to bypass conditions. Brain dam-
age according to the bypass protocols has been defined in thismodel as in our
previous studies, namely 10mL $ kg1 $min1 at 25C formild injury, 10mL
$ kg1 $ min1 at 34C for moderate injury, or circulatory arrest at 25C for
severe injury. The duration of the ultra–low-flow (ULF) bypass or hypother-
mic circulatory arrest (HCA) period was 60 minutes in each setting.
Aprotinin dosing schedules. No aprotinin (Trasylol; Bayer, West
Haven, Conn) was administered in the control group (group C). Aprotinin,
30,000 KIU/kg, was added to the pump prime in the low-dose group (group
L). An intravenous bolus infusion of aprotinin of 30,000 KIU/kg was ad-
ministered as the loading dose, as well as in the pump prime, followed by
maintenance infusion of aprotinin of 10,000 KIU $ kg1 $ h1 in the standard
full-dose group (group SF). This dosing regimen was doubled in the double
full-dose group (group DF). For all dosing regimens, aprotinin was stopped
during HCA and at 5 minutes after weaning from CPB.
CPB Technique
The CPB circuit consisted of a roller pump, membrane oxygenator
(Minimax; Medtronic, Inc, Anaheim, Calif), and sterile tubing with a 40-
mm arterial filter. Fresh whole blood from a donor pig was transfused into
the prime to adjust the hematocrit level to 30%. Methylprednisolone (30
mg/kg), furosemide (0.25mg/kg), sodium bicarbonate 7.4% (10 mL), ceph-
azolin sodium (25 mg/kg), fentanyl (50 mg/kg), and pancuronium (0.5 mg/
kg) were added to the prime. The pH-stat strategy was used (sweep gas 95%
O2/5%CO2). The gas flowwas fixed at 3 L/min to obtain an arterial PCO2 of
40 to 45 mm Hg (corrected to esophageal temperature). After baseline re-
cordings, CPB with a flow rate of 100 mL $ kg1 $ min1 was started, and
the animals were perfused for 10 minutes at normothermia (esophageal tem-
perature, 37C). Ventilation was stopped after the establishment of CPB.
The piglets underwent 40 minutes of cooling on CPB to an esophageal tem-
perature of 25C or 34C. After cooling, HCA or ULF perfusion at a flow
rate of 10 mL $ kg1 $min1 was initiated for 60 minutes. Before rewarming,
sodium bicarbonate 7.4% (10 mL), methylprednisolone (30mg/kg), furose-
mide (0.25 mg/kg), and mannitol (0.5 g/kg) were administered into the
pump. During 40 minutes of rewarming, animals were warmed to 37C
with a flow rate of 100 mL $ kg1 $ min1. The heart was defibrillated, ifrgery c June 2009
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Snecessary. Ventilation (100% oxygen) was started 10 minutes before wean-
ing from CPB. Also, dopamine was administered by means of continuous
drip infusion, if necessary. Protamine (5 mg/kg) was administered intrave-
nously after the animal was hemodynamically stable. The wounds were
closed in a sterile fashion.
Postoperative Management
Animals remained sedated and paralyzed with a continuous infusion of
fentanyl (50 mg $ kg1 $ h1), midazolam (0.2 mg $ kg1 $ h1), and pancuro-
nium (0.2mg $ kg1 $ h1) andweremechanically ventilatedwith a gradually
decreasing oxygen fraction. They were monitored continuously for 12 hours
after CPB. The chest tubes were removed, and the animals were weaned
from ventilation and extubated.
On postoperative day 4, all surviving piglets were sedated by means of
intramuscular induction with ketamine (20 mg/kg) and xylazine (4 mg/
kg) and anesthetized with intravenous fentanyl (50 mg/kg). After a midline
sternotomy, heparin (300 IU/kg) was administered, and a cannula was in-
serted into the bovine trunk. One liter of Plasmalyte solution (Baxter, Deer-
field, Ill) was infused through the bovine trunk. Blood was suctioned from
the superior vena cava until the perfusate was clear of blood. Then 3 L of
10% formalin solution was perfused through the brain in the same manner
to accomplish perfusion fixation. The entire head of the piglet was immersed
in 10% formalin for a week, and the brain was harvested and fixed with
10% formalin solution for histologic assessment.11,18-20
Data Collection
Arterial pressure was monitored continuously throughout each experi-
ment and was recorded every 10 minutes.
Blood gas analyses. Blood gases, including hematocrit values, were
measured at baseline; the end of normothermic bypass; 20 and 40 minutes
during cooling; every 15 minutes during low flow; 5, 15, 30 and 40 minutes
after beginning rewarming; and after the procedure, as needed, with a blood
gas analyzer (Bayer 860, Bayer Healthcare).
NIRS. A pair of fiberoptic optodes was attached to the head of the animal
with a probe holder after induction of anesthesia. The spacing of optodeswas
4.0 cm in the coronal plane. These 2 optodes, a transmitter, and a receiver of
laser light of near-infrared wavelength, were connected to the NIRS device
(NIRO-300; Hamamatsu Photonics KK, Hamamatsu City, Japan). This de-
vice calculated the tissue oxygenation index (TOI) from the relative concen-
tration changes in oxyhemoglobin and deoxyhemoglobin concentrations and
with calculation of the optical path length.19,21 Data were recorded every 10
seconds after the induction of anesthesia and for 3 hours after weaning from
CPB. Average TOI, which correlates withminimumTOI and TOI at 15min-
utes after the onset of ULF or HCA, was calculated.20
Renal function. Serum creatinine and blood urea nitrogen (BUN)
levels were assessed at baseline and on postoperative day 1.
Aprotinin concentration. Aprotinin concentrations weremeasured
at baseline, the end of cooling, the end of rewarming, and 3 hours and 12
hours after bypass by using the Uni-test (Unicorn Diagnostics Ltd, London,
United Kingdom).22 The blood samples were immediately centrifuged, and
the plasma was frozen and stored at80C until measurement.
Neurologic and behavioral evaluations. After the operation,
neurologic and behavioral evaluations were performed at 24-hour intervals
beginning on postoperative day 1, as described previously.18-21 The neuro-
logic deficit score (NDS; 500 ¼ brain death, 0 ¼ normal) and overall per-
formance category (5 ¼ brain death, 1 ¼ normal) were determined by an
animal care technician under the supervision of the senior veterinarian
blinded to the experimental protocol.
Histologic assessment. The preparation of the cerebral specimens
and the details of histologic analyses have been described previously.18-21
Twenty-four areas, including the neocortex, hippocampus, dentate gyrus,
caudate nucleus, thalamus, and cerebellum,were examined.Histologic dam-
age was scored by using the following criteria: 5, cavitated lesions withThe Journal of Thoracic and Cnecrosis; 4, significant damage to neurons; 3, large clusters of injured neu-
rons; 2, small clusters of damaged neurons; 1, isolated neuronal damage;
and 0, normal. Scores were summed to determine the total HS (range, 0–
120).A single neuropathologist examined all specimens in a blinded fashion.
Statistical Analysis
Physiologic variables were compared among the 3 bypass conditions be-
fore and after CPB by using 1-way analysis of variance (ANOVA) with a
2-tailed a-level to protect against committing type I errors (ie, false-positive
results).23 Mean changes in aprotinin levels and TOI (% TOI) were evalu-
ated across different time points by using repeated-measures ANOVA with
Greenhouse–Geisser F tests to assess the effects of dose and bypass condi-
tion.24 NDSs and total HSs were analyzed by using 2-way ANOVAwith the
Bonferroni adjustment to determine whether these scores were related to dif-
ferences in aprotinin dose and bypass condition. The linear relationship be-
tween NDS and aprotinin concentration was measured for the 33 piglets in
the ULF bypass groups by using a Pearson correlation and linear regression
model to derive a prediction equation of the form y ¼ b0þ b1x, where b0
denotes the intercept and b1 represents the slope coefficient for the aprotinin
concentration at the end of cooling.25 Renal function was evaluated at base-
line and postoperative day 1, whereby changes in creatinine and BUN levels
were assessed with paired t tests and differences in the D BUN between
aprotinin dose groups was compared by means of repeated-measures AN-
OVA. Linear regression analysis was applied to determine whether body
weight was associated with the D BUN and whether this relationship was
dependent on aprotinin dose and bypass condition. Statistical analysis
was performed with the SPSS software package (version 16.0; SPSS, Inc,
Chicago, Ill). Power analysis was conducted a priori and indicated that
a minimum of 12 animals was needed in each aprotinin dose and the control
group and randomized equally to the bypass conditions (n ¼ 4) to achieve
80% power for detecting significant dose-response effects with respect to
% TOI, NDS, and total HS based on ANOVA (version 7.0; nQuery Advi-
sor, Statistical Solutions, Saugus, Mass).
RESULTS
Forty-eight of the 54 animals survived the entire protocol
and were killed on postoperative day 4 for histologic assess-
ment. Four piglets subjected to 10 mL $ kg1 $min1 at 34C
receiving a low dose of aprotinin (n ¼ 2), a double full dose
of aprotinin (n ¼ 2), or both died after weaning from CPB
with sudden ventricular fibrillation. Data from these animals
were excluded for analysis. Two piglets subjected to HCA at
25C or ULF at 34C receiving no aprotinin died on postop-
erative day 1 with sudden death. Data from these piglets
were included for analysis, except histologic analysis.
FIGURE 1. Experimental protocol. Cre, Creatinine; BUN, blood urea ni-
trogen; NIRS, near-infrared spectroscopy; NDS, neurologic deficit score;
OPC, overall performance category; CPB, cardiopulmonary bypass.ardiovascular Surgery c Volume 137, Number 6 1523
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STABLE 1. Physiologic variables during and after cardiopulmonary bypass*
Ultra–low-flow bypass groups HCA group
Variable 25C, 10 mL $ kg1 $ min1 (n ¼ 16) 34C, 10 mL $ kg1 $ min1 (n ¼ 17) 25C, circulatory arrest (n ¼ 17)
Baseline
Temperature (C) 36.1  1.0 35.9  0.7 36.1  0.8
MAP (mm Hg) 69.1  13.9 68.9  11.5 71.5  13.0
pH 7.51  0.05 7.51  0.05 7.52  0.03
PaO2 (mm Hg) 83.1  6.2 74.5  15.0 79.7  9.8
PaCO2 (mm Hg) 39.1  4.4 40.4  4.3 39.6  2.6
Hematocrit (%) 29.1  3.3 29.7  3.0 28.3  2.2
SvO2 (%) 74.6  6.2 72.7  8.3 72.3  6.2
12 h after CPB (FIO2 ¼ 0.25)
Temperature (C) 37.2  0.5 37.1  0.8 37.0  0.4
MAP (mm Hg) 90.9  15.8 91.4  15.0 89.7  14.4
pH 7.49  0.06 7.51  0.05 7.51  0.07
PaO2 (mm Hg) 96.4  15.2 96.4  24.4 90.3  19.5
PaCO2 (mm Hg) 41.7  3.5 40.5  3.7 41.4  4.8
Hematocrit (%) 30.7  2.9 30.4  2.3 30.1  1.9
SvO2 (%) 74.8  16.4 74.2  10.4 80.5  10.0
Data are presented as means  standard deviation. HCA, Hypothermic circulatory arrest; MAP, mean arterial pressure; SvO2, oxygen saturation of venous blood; CPB, cardiopul-
monary bypass; FIO2, fraction of inspired oxygen. *No significant differences were observed for any variable. Groups were also compared at the end of cooling, rewarming for 5
minutes, the end of bypass, and 6 hours after cardiopulmonary bypass, and no differences were found (2-tailed P< .01, 1-wat analysis of variance, as the criterion for statistical
significance to protect against type I errors caused by multiple comparisons).Physiologic Parameters and Bypass-Related
Variables
There were no significant differences at baseline for body
weight, mean blood pressure, body temperature, blood
gases, and hematocrit values between bypass conditions.
Also, no significant differences were observed for any pa-
rameters at the end of cooling, rewarming for 5 minutes,
the end of bypass, and 6 hours after CPB (2-tailed P<
.01, 1-way ANOVA, as the criterion for statistical signifi-
cance to protect against type I errors caused by multiple
comparisons; Table 1).
Aprotinin Concentration
As anticipated, group DF had significantly higher aproti-
nin concentrations than the other groups (P< .01). Also,
group SF had a higher concentration than groups L and C
(P< .02). Group L did not reach a significant difference
against group C. Aprotinin concentrations reached a peak
value at the end of cooling, namely 289.8  72.1 KIU/mL
in group DF, 150.6  103.2 KIU/mL in group SF and
64.5  61.7 KIU/mL in group L, and decreased gradually
in all dosing schedules (Figure 2).
Tissue Oxygenation Index
TOI increased during cooling, decreased rapidly from the
onset ofULF orHCA, and reached a nadir in all animals. Dur-
ing HCA at 25C, aprotinin did not influence TOI, even in
groupDF.However, duringULF at 25Cor 34C, the average
TOI was 51.9%  4.4%, 49.1%  4.1%, 48.6%  3.7%,
and 46.1%  4.9% in groups DF, SF, and L and the control1524 The Journal of Thoracic and Cardiovascular Sugroup, respectively. Values in group DF were significantly
higher than those in the control group (P< .05, Figure 3).
Neurologic and Behavioral Evaluations
NDSs and overall performance categories showed rela-
tively rapid recovery in all surviving animals. Aprotinin
FIGURE 2. The aprotinin concentration was significantly higher (*) in the
double full-dose group compared with concentrations seen in the standard
full-dose, low-dose, and control groups at the end of cooling, end of bypass,
3 hours after cardiopulmonary bypass (CPB; all P<.001), and 12 hours af-
ter cardiopulmonary bypass (all P<.05). Concentrations were significantly
higher in the standard full-dose group (y) than in the low-dose and control
groups at the end of cooling and the end of bypass (all P<.01). Concentra-
tions in the low-dose group were not significantly different from those in the
control group at any time point (all P> .25). Analysis was determined by
using repeated-measures analysis of variance with Bonferroni-adjusted
group comparisons. SF, Standard full dose; DF, double full dose.rgery c June 2009
Iwata et al Cardiopulmonary SupportFIGURE 3. The average tissue oxygenation index during ultra–low-flow (ULF) bypass at 25C or 34C in the double full-dose (DF) group was significantly
higher than that seen in the control group (P<.05, analysis of variance with group comparisons by using the Tukeymethod). Aprotinin improved oxygenation
during ultra–low-flow bypass independent of bypass temperature. Error bars denote standard errors. SF, Standard full dose; BL, baseline.was associated with significantly improved neurologic
scores on postoperative day 1 after ULF at 25C or 34C
(P< .05) but not after HCA (P ¼ .57, Figure 4). Linear re-
gression indicated a strong dose-response relationship, with
higher aprotinin doses having the best neurologic scores af-
ter ULF, where doses are as follows: 0, none; 1, low dose; 2,
standard full dose; and 3, double full dose (r ¼0.73, P<The Journal of Thoracic and C.01, Figure 5). Also, a higher aprotinin concentration at the
end of cooling was correlated to lower NDSs (r ¼0.57,
P< .01, Figure 6).
Histologic Assessment
Histologic damage was found predominantly in the neo-
cortex, hippocampus, and caudate nucleus. Three animalsC
P
SFIGURE 4. Neurologic deficit scores (NDS) on postoperative day 1 according to aprotinin dose for the 3 bypass conditions. Neurologic deficit scores were
significantly lower (ie, improved) with aprotinin after ultra–low-flow bypass at 25C or 34C but not after hypothermic circulatory arrest (P ¼ .57). After
ultra–low-flow bypass at 25C, neurologic deficit scores were significantly lower in the double full-dose (DF) group compared with those in the control group
(*P<.001) and the single full-dose (SF) group (P ¼ .02). Neurologic deficit scores were significantly lower in the single full-dose group than in the control
group (yP ¼ .03). After ultra–low-flow bypass at 34C, neurologic deficit scores were significantly lower in the aprotinin double full-dose group compared
with those in the control group (P<.001) and in the single full-dose (y) and low-dose (z) groups compared with the control group (both P¼ .02). Analysis was
performed by using 2-way analysis of variance with the Bonferroni adjustment for multiple comparisons. Error bars denote standard deviations. NS, Not
significant.ardiovascular Surgery c Volume 137, Number 6 1525
Cardiopulmonary Support Iwata et al
C
P
Sassigned to ULF at 25C with no aprotinin or a standard full
dose or ULF at 34C with a standard full dose of aprotinin
had no brain damage. In control animals, as anticipated,
there were significant differences in total HSs between by-
pass conditions (P< .01) as follows: mild injury (ULF at
25C), 0.8  0.5; moderate injury (ULF at 34C), 9.8 
7.2; and severe injury (HCA at 25C), 14.8 4.2 (Figure 7).
Aprotinin did not influence histologic outcomes in any by-
pass conditions, although scores after the condition of
ULF at 25C were significantly lower than those after
ULF at 34C or HCA at 25C (Figure 7).
Renal Function
Overall creatinine and BUN values significantly increased
at postoperative day 1, from 0.8  0.3 to 1.3  0.8 mg/dL
and from 8.9 3.8 to 30.1 10.9 mg/dL, respectively. Mul-
tivariate analysis showed that bypass conditions and aproti-
nin dosing schedules had no influence on renal function
(Figure 8). Also, the peak aprotinin concentration did not
correlate with renal outcomes. Lower body weight was the
only predictor of a higher BUN value on postoperative 1
(r ¼0.39, P< .01, Figure 9).
DISCUSSION
This study demonstrates that aprotinin improves func-
tional neurologic recovery in animals with mild or moderate
FIGURE 5. Linear relationship between aprotinin dose and neurologic
scores for the combined group of 33 piglets undergoing ultra–low-flow
bypass (n ¼ 16 at 25C and n ¼ 17 at 34C). Linear regression analysis
indicated a strong dose-response relationship, with higher aprotinin doses
resulting in significantly lower neurologic scores (Pearson r ¼0.73, P<
.001). The linear equation specifies the aprotinin dosing schedule as follows:
none, 0; low dose, 1; standard full dose, 2; and double full dose, 3. The
model fit was judged to be very good judging from the coefficient of deter-
mination (adjusted R2 ¼ 0.51), indicating that more than 50% of the vari-
ability in neurologic scores can be accounted for by aprotinin dosing. The
95% confidence interval for the mean neurologic deficit score (NDS) shows
3 piglets in the control group (no aprotinin) with very high scores. No linear
relationship was observed in the hypothermic circulatory arrest group (P ¼
.22, n ¼ 17). POD1, Postoperative day 1.1526 The Journal of Thoracic and Cardiovascular Subrain injury after ULF CPB. The beneficial effects of apro-
tinin are dose dependent over the dosage regimens applied
in this study. The beneficial effect of aprotinin was not
seen in animals with severe brain injury after circulatory
FIGURE 6. Linear regression analysis depicts a moderately strong inverse
relationship between the aprotinin concentration at the end of cooling and
neurologic deficit score (NDS) on postoperative day 1 (POD1; Pearson
r¼0.57, P<.001). The regression line predicts a lower neurologic deficit
score with higher aprotinin concentrations (solid line). Analysis is based on
piglets undergoing ultra–low-flow bypass (n¼ 33) because the hypothermic
circulatory arrest group did not show a relationship between aprotinin con-
centration and neurologic deficit score. Multiple regression revealed that al-
though neurologic deficit scores tend to be higher for 34C and 10 mL than
for 25C and 10 mL, the significance of aprotinin concentration as a predic-
tor of neurologic deficit score stands for both conditions.
FIGURE 7. Total histologic scores according to aprotinin dose for the 3
bypass conditions. Analysis of variance with Bonferroni comparisons re-
vealed no significant differences in total histologic scores (HS) among the
4 groups (control and aprotinin doses) for any of the bypass conditions
(25C and 10 mL, P ¼ .12; 34C and 10 mL, P ¼ .82; hypothermic circu-
latory arrest [HCA], P ¼ .10). Error bars denote standard deviations. SF,
Single full-dose; DF, double full-dose; NS, not significant.rgery c June 2009




arrest. This result suggests that aprotinin might have influ-
enced blood flow under ULF states and is consistent with
our previous studies, which suggest that vascular preserva-
tion is an important mechanism of action of aprotinin. On
the other hand, Anttila and coworkers11 reported that aproti-
nin improved NDSs, even after DHCA at 15C. This differ-
ence might be explained by the severity of brain injury,
which was moderate in the study by Anttila and coworkers,
whereas it was severe in our study.
In our study aprotinin did not improve HSs in any bypass
condition, including those in which there was an improve-
ment in NDSs. Anttila and coworkers11 also reported that
aprotinin did not improve HSs after DHCA. We have re-
FIGURE 8. Renal function evaluated by changes in creatinine and blood
urea nitrogen (BUN) values. Creatinine values (A) increased on postopera-
tive day 1 (*P< .01 and yP< .05, paired t tests), although the amount of
change did not differ with respect to aprotinin dose (P¼ .08, analysis of var-
iance). Blood urea nitrogen (B) values increased significantly in all groups
by approximately 3-fold (all P< .01). Error bars denote standard devia-
tions. Additional statistical analysis with repeated-measures analysis of var-
iance indicated that changes in creatinine values were not significantly
related to aprotinin dose (P ¼ .79) or specific bypass conditions (P ¼
.18) and changes in blood urea nitrogen values were not dependent on apro-
tinin dose (P ¼ .36) or bypass conditions (P ¼ .13). SF, Single full-dose;
DF, double full-dose.The Journal of Thoracic and Cported previously that NDSs at postoperative day 1 correlate
with total HSs.26 In this study NDSs at postoperative day 1
after ULF did not correlate with total HSs. This discrepancy
might result from our histologic evaluation method, which
focused on necrotic neuronal cell death. Kurth and asssoci-
ates27 reported that apoptosis plays a key role in neuronal
cell death after DHCA. It is known that aprotinin reduces ap-
optosis. For example, Eser and colleagues28 reported that
aprotinin decreased apoptotic cell death after brain ischemia.
We also have confirmed that aprotinin reduces apoptotic cell
death caused by serum deprivation at the concentration of
100 KIU/mL using a cell culture model (data not shown).
Thus reduction of apoptotic neuronal cell death by aprotinin
might contribute to improved neurologic outcome.
Renal Function
Aprotinin did not influence renal function with any dosing
regimen in this study, although creatinine and BUN values
increased at postoperative day 1 in all conditions. Lower
body weight, but not aprotinin use, was predictive of higher
BUN values at postoperative day 1 by means of multivariate
analysis.
Aprotinin has a high affinity for renal tissue and is rapidly
eliminated from the circulation, necessitating a continuous
infusion after a bolus dose to maintain a targeted concentra-
tion of aprotinin.29 The proximal tubular cells absorb and
metabolize aprotinin. Feindt and coworkers7 demonstrated
in adults that renal dysfunction could result from
tubular damage caused by aprotinin, which increases
FIGURE 9. Inverse relationship between body weight and change in blood
urea nitrogen (BUN) value (r ¼0.39, n ¼ 47). Linear regression analysis
indicates that lower body weight was predictive of a greater increase in
blood urea nitrogen values at postoperative day 1 (P<.01) and that this re-
lationship is independent of aprotinin dose and bypass conditions. For
example, a piglet weighing 9 kg is expected, on average, to have an increase
in blood urea nitrogen value of 24mg/dL, whereas a 13-kg piglet is expected
to have an increase of 14 mg/dL. The solid line represents the fitted regres-
sion line, where x is body weight in kilograms.ardiovascular Surgery c Volume 137, Number 6 1527
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Sa2-microglobulin and total protein values in urine, although
they did not find relevant changes in serum creatinine levels.
They concluded that patients with normal renal function pre-
operatively were able to compensate for both the periopera-
tive renal dysfunction caused by CPB and the additional
tubular workload imposed by aprotinin. Our data confirm
that animals with normal renal function are able to compen-
sate for the stress of surgical intervention, CPB, and aproti-
nin, even at a double full-dose regimen. This finding is
consistent with clinical reports that have looked at renal
function in children with aprotinin use. Although there has
been a trend toward higher creatinine levels postoperatively
with aprotinin use, this has not been clinically significant.30
Aprotinin Concentration
In this study aprotinin concentration reached a peak at the
end of cooling and was 150 KIU/mL in group SF and 280
KIU/mL in group DF, as determined by means of functional
assay.22 Aprotinin inhibits plasmin at a concentration of 50
KIU/mL (hemostatic effect) and kallikrein (anti-inflamma-
tory) at a concentration of 200 KIU/mL in vitro. In vivo it
is thought that a large molar excess of aprotinin up to 125
and 250 to 500 KIU/mL, respectively, is required to inhibit
plasmin and kallikrein.31 The original high-dose Hammer-
smith hospital regimen aimed to achieve at least 200 KIU/
mL, as determined by means of immunologic assay.32,33
The results of our current study support the notion that
a dose as high as double the current standard pediatric
dose might be more effective in improving functional out-
come while not impairing renal function.
Brain Oxygenation
We have reported previously that TOI is a useful monitor
of brain oxygenation during CPB and that average TOI cor-
relates with brain damage.19-21,26 In the present study double
full-dose aprotinin significantly increased TOI during ULF
but did not influence the decrease in TOI during HCA.
This result is consistent with our previous finding that apro-
tinin improves cerebrovascular protection.
Direct Neuronal Protection and the Role of the
Blood–Brain Barrier
Although our previous cell-culture studies have demon-
strated that aprotinin, like other serine protease inhibitors,
can reduce excitotoxic brain injury, the present study does
not shed light as to how important that mechanism might
be in improving functional outcome, as observed in this
study. Improved vascular protection of the brain and gener-
alized anti-inflammatory effects alone might explain the fact
that animals recovered more rapidly on the first day after sur-
gical intervention when aprotinin was used. Furthermore,
the ability of aprotinin to cross the blood–brain barrier so
as to be able to have a direct neuronal effect is not assessed
in the present study.1528 The Journal of Thoracic and Cardiovascular SCONCLUSION
Our data suggest that aprotinin improves neurologic re-
covery without compromising renal function in the piglet.
Well-designed aprotinin dose-response studies are needed
to assess the safety versus efficacy of aprotinin in the clinical
setting, particularly a double full-dose strategy. Pediatric
surgeons will continue to explore pharmacologic strategies
to reduce the hemorrhagic and inflammatory consequences
of CPB, which undoubtedly delay recovery from congenital
cardiac procedures, especially in the very young.
We thank Inger Hogan for technical support and animal care.We
also thank Laura Young for preparation of the manuscript.
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is given. Do you have any data from the neonatal animals that
you examined that are exposed to less disturbing strategies of per-
fusion to see whether there is any difference in renal function when
the aprotinin is administered? Also, do you have any normal bypass
control animals, with and without aprotinin, with respect to renal
function?
Dr Iwata. Aprotinin has a high affinity for the renal tissues and
is eliminated from the circulation by glomerular filtration, with re-
sorption by the proximal tubules. Thus a continuous infusion is
required.
We have demonstrated that both creatinine and BUN values in-
crease after surgical intervention on postoperative day 1 under the
stressful conditions of our experiment. The increases were not
influenced by any specific bypass condition or by the aprotinin dos-
ing schedules. However, we do not have data yet regarding the ef-
fect of less stressful bypass conditions with and without aprotinin.
We are presently conducting such studies.
Dr Marath. What are your thoughts about why aprotinin is pro-
tective at mild and moderate levels of neuroinjury? You know, mild
neuroinjury we can accept, but what about severe injury? Specifi-
cally, do you think this relates to an anti—inflammatory mechanism
that is going on?
Dr Iwata. Aprotinin has 3 different neuroprotective effects. As I
presented last year at this meeting, aprotinin directly protects neu-
rons against ischemic insult based on our work with neuronal cell
cultures. Aprotinin also reduces inflammation. We have also dem-
onstrated previously that aprotinin protects against mild cerebro-
vascular insult by improving the cerebral microcirculation with
reduced neutrophil activation.
Dr Marath. In your article, and I think you alluded to it in one
slide, I liked the comment you made in your introduction when you
stated correctly that the adjustment of body weight and blood level
has generally not been monitored. I think this is an important point
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Dr Aubyn Marath (Portland, Ore). I want to thank the Associ-
ation for the privilege of discussing this article. Dr Ungerleider re-
grets he cannot be here.
Dr Iwata, I was very pleased and impressed with your coping
with the language problems and also the very nice presentation
of your article. I have 4 questions, 2 of which were Dr Unger-
leider’s. I am going to read them to you.
You demonstrate a mild postsurgical increase in BUN and cre-
atinine values in your models of altered flow that is consistent re-
gardless of the dose of aprotinin and is similar when no aprotinin
in your observations.
One of the questions I wanted to ask was this. I was very im-
pressed with your histologic mapping of the target areas of the
brain. Recognizing that you have to put the pig’s head in formalin
for a week or so, have you done any cerebrovascular assessment of
the piglets? Because in human subjects, as you know, there is quite
marked variation in cerebrovascular anatomy, up to 35%, for in-
stance, in the circle of Willis variations in anatomy.
Dr Iwata. No, we have not specifically studied the cerebrovas-
cular anatomy of the piglet. We believe the ischemic insult of cir-
culatory arrest is a global insult and is not influenced by the
individual piglet anatomy.
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